{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:34:02Z","timestamp":1793093642327,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002590","name":"American Lung Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002590","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jbc.2026.113564","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:43:45Z","timestamp":1789602225000},"page":"113564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A RALGEF inhibitor suppresses lung cancer stem cell development and tumorigenesis"],"prefix":"10.1016","volume":"302","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6878-7132","authenticated-orcid":false,"given":"Raphael","family":"Jigo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6750-5682","authenticated-orcid":false,"given":"Geoffrey J.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2026.113564_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jbc.2026.113564_bib2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-Small cell lung cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jbc.2026.113564_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","article-title":"Oncogenic driver mutations in non-small cell lung cancer: past, present and future","volume":"12","author":"Chevallier","year":"2021","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.jbc.2026.113564_bib4","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/ijms22020612","article-title":"Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer","volume":"22","author":"Fois","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbc.2026.113564_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5732\/cjc.012.10098","article-title":"The genetics and biology of KRAS in lung cancer","volume":"32","author":"Westcott","year":"2013","journal-title":"Chin J. Cancer"},{"key":"10.1016\/j.jbc.2026.113564_bib6","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/j.molcel.2024.06.027","article-title":"Functional and structural insights into RAS effector proteins","volume":"84","author":"Mozzarelli","year":"2024","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jbc.2026.113564_bib7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/nsb0698-422","article-title":"Structural basis for the interaction of Ras with RalGDS","volume":"5","author":"Huang","year":"1998","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.jbc.2026.113564_bib8","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.cellsig.2010.05.010","article-title":"RalGDS family members couple Ras to Ral signalling and that's not all","volume":"22","author":"Ferro","year":"2010","journal-title":"Cell Signal."},{"key":"10.1016\/j.jbc.2026.113564_bib9","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/sj.onc.1202425","article-title":"Plasma membrane recruitment of RalGDS is critical for ras-dependent Ral activation","volume":"18","author":"Matsubara","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.jbc.2026.113564_bib10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/bs.ircmb.2020.10.005","article-title":"The RAL signaling network: cancer and beyond","volume":"361","author":"Apken","year":"2021","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.jbc.2026.113564_bib11","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.lungcan.2012.03.007","article-title":"Inhibition of RalA signaling pathway in treatment of non-small cell lung cancer","volume":"77","author":"Male","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jbc.2026.113564_bib12","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.63807","article-title":"RAL GTPases mediate EGFR-driven intestinal stem cell proliferation and tumourigenesis","volume":"10","author":"N\u00e1szai","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.jbc.2026.113564_bib13","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.stem.2019.02.002","article-title":"RAL GTPases drive intestinal stem cell function and regeneration through internalization of WNT signalosomes","volume":"24","author":"Johansson","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jbc.2026.113564_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2024.100197","article-title":"Mechanism of TBK1 activation in cancer cells","volume":"3","author":"Hu","year":"2024","journal-title":"Cell Insight"},{"key":"10.1016\/j.jbc.2026.113564_bib15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ncb2953","article-title":"An integrin \u03b23-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition","volume":"16","author":"Seguin","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.jbc.2026.113564_bib16","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.molonc.2014.03.020","article-title":"RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC)","volume":"8","author":"Ezzeldin","year":"2014","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.jbc.2026.113564_bib17","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.3389\/fimmu.2020.01280","article-title":"Cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies","volume":"11","author":"Walcher","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.jbc.2026.113564_bib18","doi-asserted-by":"crossref","first-page":"8721","DOI":"10.7150\/thno.41648","article-title":"Stem cell programs in cancer initiation, progression, and therapy resistance","volume":"10","author":"Huang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jbc.2026.113564_bib19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ccr.2005.04.030","article-title":"Activation of RalA is critical for Ras-induced tumorigenesis of human cells","volume":"7","author":"Lim","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2026.113564_bib20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ccr.2005.01.029","article-title":"RalGDS is required for tumor formation in a model of skin carcinogenesis","volume":"7","author":"Gonz\u00e1lez-Garc\u00eda","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2026.113564_bib21","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1128\/MCB.00955-07","article-title":"Activation of the RalGEF\/Ral pathway promotes prostate cancer metastasis to bone","volume":"27","author":"Yin","year":"2007","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.jbc.2026.113564_bib22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/sj.onc.1208094","article-title":"The small G-protein RalA stimulates metastasis of transformed cells","volume":"24","author":"Tchevkina","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.jbc.2026.113564_bib23","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/j.cub.2012.09.013","article-title":"Genetic deletion of RALA and RALB small GTPases reveals redundant functions in development and tumorigenesis","volume":"22","author":"Peschard","year":"2012","journal-title":"Curr. Biol."},{"key":"10.1016\/j.jbc.2026.113564_bib24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40164-023-00453-8","article-title":"The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC","volume":"12","author":"Batrash","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.jbc.2026.113564_bib25","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/1535-7163.MCT-21-0201","article-title":"Characterization of KRAS mutation subtypes in non-small cell lung cancer","volume":"20","author":"Judd","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jbc.2026.113564_bib26","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.3390\/cancers16213676","article-title":"Comparative efficacy of Adagrasib and Sotorasib in KRAS G12C-Mutant NSCLC: insights from pivotal trials","volume":"16","author":"Peng","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jbc.2026.113564_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2025.1537523","article-title":"Sotorasib resistance triggers epithelial-mesenchymal transition and activates AKT and P38-mediated signaling","volume":"12","author":"Megid","year":"2025","journal-title":"Front Mol. Biosci."},{"key":"10.1016\/j.jbc.2026.113564_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.110809","article-title":"RALGEF inhibitors suppress RAS driven pancreatic cancer and metastasis","volume":"301","author":"Donninger","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2026.113564_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176727","article-title":"Targeting the RAS upstream and downstream signaling pathway for cancer treatment","volume":"979","author":"Hossain","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jbc.2026.113564_bib30","doi-asserted-by":"crossref","first-page":"34729","DOI":"10.1074\/jbc.M110.116756","article-title":"Aberrant overexpression of the Rgl2 Ral small GTPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through Ral-dependent and Ral-independent mechanisms","volume":"285","author":"Vigil","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2026.113564_bib31","first-page":"139","article-title":"RALBP1\/RLIP76 mediates multidrug resistance","volume":"30","author":"Drake","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jbc.2026.113564_bib32","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.bcp.2005.05.005","article-title":"Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin","volume":"70","author":"Singhal","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jbc.2026.113564_bib33","article-title":"The exocyst complex in health and disease","volume":"4","author":"Urdiroz","year":"2016","journal-title":"Front. Cell Develop. Biol."},{"key":"10.1016\/j.jbc.2026.113564_bib34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/jb\/mvv029","article-title":"Crucial mediators of exocytosis and tumourigenesis","volume":"157","author":"Shirakawa","year":"2015","journal-title":"J. Biochem."},{"key":"10.1016\/j.jbc.2026.113564_bib35","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1128\/MCB.24.13.5746-5756.2004","article-title":"RalA but not RalB enhances polarized delivery of membrane proteins to the basolateral surface of epithelial cells","volume":"24","author":"Shipitsin","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.jbc.2026.113564_bib36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.devcel.2005.07.013","article-title":"Drosophila exocyst components Sec5, Sec6, and Sec15 regulate DE-Cadherin trafficking from recycling endosomes to the plasma membrane","volume":"9","author":"Langevin","year":"2005","journal-title":"Dev. Cell"},{"key":"10.1016\/j.jbc.2026.113564_bib37","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.bcp.2011.06.005","article-title":"Yellow submarine of the Wnt\/Frizzled signaling: submerging from the G protein harbor to the targets","volume":"82","author":"Koval","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jbc.2026.113564_bib38","first-page":"165","article-title":"Cancer stem cells and individualized therapy","volume":"4","author":"Chumsri","year":"2007","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.jbc.2026.113564_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/cddiscovery.2017.23","article-title":"RalBP1 and p19-VHL play an oncogenic role, and p30-VHL plays a tumor suppressor role during the blebbishield emergency program","volume":"3","author":"Jinesh","year":"2017","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.jbc.2026.113564_bib40","first-page":"6791","article-title":"Utilization of lung cancer cell lines for the study of lung cancer stem cells","volume":"15","author":"Wang","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jbc.2026.113564_bib41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-4939-7401-6_4","article-title":"Evaluation and isolation of cancer stem cells using ALDH activity assay","volume":"1692","author":"Mele","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jbc.2026.113564_bib42","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/0717-6287-47-66","article-title":"Cancer stem cells--the current status of an old concept: literature review and clinical approaches","volume":"47","author":"Fulawka","year":"2014","journal-title":"Biol. Res."},{"key":"10.1016\/j.jbc.2026.113564_bib43","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1101\/gad.943001","article-title":"Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras","volume":"15","author":"Jackson","year":"2001","journal-title":"Genes Dev."},{"key":"10.1016\/j.jbc.2026.113564_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063432","article-title":"Administration of bleomycin via the oropharyngeal aspiration route leads to sustained lung fibrosis in mice and rats as quantified by UTE-MRI and histology","volume":"8","author":"Egger","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2026.113564_bib45","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Sig. Transduct. Target. Ther."},{"key":"10.1016\/j.jbc.2026.113564_bib46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1947601911408079","article-title":"RAS interaction with PI3K: more than just another effector pathway","volume":"2","author":"Castellano","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.jbc.2026.113564_bib47","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/sj.embor.embor899","article-title":"RAL GTPases are linchpin modulators of human tumour-cell proliferation and survival","volume":"4","author":"Chien","year":"2003","journal-title":"EMBO Rep."},{"key":"10.1016\/j.jbc.2026.113564_bib48","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/emboj.2010.7","article-title":"Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival","volume":"29","author":"Drosten","year":"2010","journal-title":"EMBO J."},{"key":"10.1016\/j.jbc.2026.113564_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104754","article-title":"Ral GTPase promotes metastasis of pancreatic ductal adenocarcinoma via elevation of TGF-\u03b21 production","volume":"299","author":"Cao","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2026.113564_bib50","doi-asserted-by":"crossref","first-page":"5958","DOI":"10.1128\/MCB.21.17.5958-5969.2001","article-title":"Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways","volume":"21","author":"Ward","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.jbc.2026.113564_bib51","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jbc.2026.113564_bib52","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1758834015571111","article-title":"MEK and PI3K inhibition in solid tumors: rationale and evidence to date","volume":"7","author":"Jokinen","year":"2015","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.jbc.2026.113564_bib53","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.tips.2022.03.011","article-title":"Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer","volume":"43","author":"Ganguly","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jbc.2026.113564_bib54","article-title":"Acquired resistance to sotorasib in KRASG12C mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition mediated by 4E-BP1 regulator of cap-dependent translation","volume":"14","author":"Meraz","year":"2025","journal-title":"eLife"},{"key":"10.1016\/j.jbc.2026.113564_bib55","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41416-022-02032-w","article-title":"PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib","volume":"128","author":"Chan","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbc.2026.113564_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110993","article-title":"KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy","volume":"39","author":"Ryan","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.jbc.2026.113564_bib57","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s43018-023-00575-2","article-title":"Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS","volume":"4","author":"Adachi","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.jbc.2026.113564_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1328728","article-title":"Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer","volume":"14","author":"Chour","year":"2024","journal-title":"Front Oncol."},{"key":"10.1016\/j.jbc.2026.113564_bib59","doi-asserted-by":"crossref","first-page":"9327","DOI":"10.1021\/bi992964c","article-title":"Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin","volume":"39","author":"Awasthi","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.jbc.2026.113564_bib60","first-page":"717","article-title":"Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer","volume":"30","author":"Singhal","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jbc.2026.113564_bib61","first-page":"1505","article-title":"Role of RLIP76 in doxorubicin resistance in lung cancer","volume":"34","author":"Vatsyayan","year":"2009","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jbc.2026.113564_bib62","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1158\/0008-5472.CAN-06-4124","article-title":"Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1)","volume":"67","author":"Singhal","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2026.113564_bib63","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/ncb728","article-title":"The exocyst is a Ral effector complex","volume":"4","author":"Moskalenko","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.jbc.2026.113564_bib64","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1128\/MCB.19.9.6333","article-title":"Differential roles of Akt, Rac, and Ral in R-Ras-mediated cellular transformation, adhesion, and survival","volume":"19","author":"Osada","year":"1999","journal-title":"Mol. Cell Biol"},{"key":"10.1016\/j.jbc.2026.113564_bib65","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1091\/mbc.e06-08-0765","article-title":"R-Ras regulates exocytosis by Rgl2\/Rlf-mediated activation of RalA on endosomes","volume":"18","author":"Takaya","year":"2007","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.jbc.2026.113564_bib66","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/nprot.2009.95","article-title":"Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase","volume":"4","author":"DuPage","year":"2009","journal-title":"Nat. Protoc."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826024361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826024361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:43:28Z","timestamp":1793090608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925826024361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":66,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0021925826024361"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2026.113564","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A RALGEF inhibitor suppresses lung cancer stem cell development and tumorigenesis","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2026.113564","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"113564"}}